Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients
- 23 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1093-1099
Abstract
Background: The increasing incidence and prevalence of breast cancer alongside diagnostic and treatment technology advances have produced a debate about the financial burden cancer places on the healthcare system and concerns about access. Methods: This study was conducted at 51 hospitals belonging to the Breast Cancer Study Group of the Japan Clinical Oncology Group using a web-based survey. The survey period conducted from July 2021 to June 2022. The study population included patients with metastatic breast cancer who received the related treatment as their first-line therapy. The proportion of patients who selected that regimen as their first-line treatment was tabulated. The total cost increase for each current standard therapy in comparison to conventional treatments was calculated. Results: A total of 702 patients (pts) were surveyed. Of those enrolled, 342 (48.7%) received high-cost treatment [estimated monthly drug costs exceeding ~500 000 Japanese Yen (JPY)]. Of these, 16 pts (4.7%) were receiving very high-cost treatment, amounting to more than 1 000 000 JPY per month. Fifty three (15.5%) of the patients who received high-cost treatment were 75 years of age or older. Of these, 1 pt (0.3%) were receiving very high-cost treatment. Analyses of incremental costs by current drugs showed that abemaciclib was costly with total additional cost of 6 365 670 JPY per patient. The total additional cost of the regimen per patient that included palbociclib was the second highest at 4011248 JPY, followed by atezolizumab at 3209033 JPY. Conclusions: The findings indicate that evaluating the financial implications of high-cost treatments requires considering not only drug prices but also analysis of total cost increase.Keywords
Funding Information
- National Cancer Center Research and Development Funds (2023-J-03)
- Research Fund of the National Federation of Health Insurance Societies
This publication has 25 references indexed in Scilit:
- Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectivesBreast Cancer, 2023
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisAnnals of Oncology, 2021
- Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroupsnpj Breast Cancer, 2021
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialThe Lancet, 2020
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2020
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancernpj Breast Cancer, 2019
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upBreast Cancer Research and Treatment, 2019
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast CancerNew England Journal of Medicine, 2015
- Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)Breast Cancer Research and Treatment, 2013
- The High Cost of Cancer Drugs and What We Can Do About ItMayo Clinic Proceedings, 2012